











[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

# Influenza Viral Pathogenesis

Project Number	Contact PI/Project Leader	Awardee Organization
1ZIAAI000986-13	TAUBENBERGER, JEFFERY	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

## Description

### Abstract Text

Influenza A viruses (IAV) are significant human pathogens causing yearly epidemics and occasional pandemics. Past pandemics have resulted in significant morbidity and mortality. The 1918 influenza **pandemic** was thought to have resulted in the death of at least 675,000 people in the U.S., and 40 million people worldwide. Pandemics in 1957 and 1968, while less severe, were also of major public health importance. A novel influenza A virus of swine origin became **pandemic** in 2009, causing the first **pandemic** in 41 years. In addition, annual epidemic influenza causes are also very significant resulting in up to 80,000 deaths in the US annually. Highly pathogenic avian H5N1 viruses continue to circulate enzootically in poultry in many countries and continue to cause human infections. Recently a novel avian H7N9 strain emerged in China also causing human infections and fatalities. A variety of experimental pathogenesis studies to model host adaptation, map viral virulence factors and host factors in disease progression, evaluate novel therapeutics and vaccines were performed. Influenza virus infections are a global public health problem, with a significant impact of morbidity and mortality from both annual epidemics and pandemics. The current strategy for preventing annual influenza is to develop a new vaccine each year against specific circulating virus strains. Because these vaccines are unlikely to protect against an antigenically divergent strain or a new **pandemic** virus with a novel hemagglutinin (HA) subtype, there is a critical need for vaccines that protect against all influenza A viruses, a so-called "universal" vaccine. Recent work has suggested that such broadly protective, or "universal", influenza virus vaccines might be achievable using vaccine strategies that target conserved B- and T-cell epitopes. Efforts to develop broadly protective influenza virus vaccines were emphasized during the reporting period. A vaccine cocktail expressing four low pathogenicity avian influenza virus hemagglutinin (HA) subtypes (H1, H3, H5, and H7) has proven very efficacious in mouse and ferret studies. Initial studies using HA-expressing VLPs produced in baculovirus have been promising. More recently, vaccines consisting of mixtures of inactivated low pathogenicity avian influenza viruses expressing different HA subtypes have also been shown to be very promising as broadly protective vaccines when delivered either intramuscularly or intranasally. These vaccine cocktails provide 100% protection against lethal challenge with heterosubtypic influenza A viruses in mice and significant protection in ferret studies, and result in the development of antibodies against the hemagglutinin head and stalk, antibodies to neuraminidases, along with an increase in CD8+ influenza-specific T cells.

### Public Health Relevance Statement

Data not available.

### NIH Spending Category











Biodefense	Biotechnology	Emerging Infectious Diseases	Immunization
Infectious Diseases	Influenza	Pneumonia & Influenza	Prevention
Vaccine Related			

### Project Terms

Antibodies	Avian Influenza	Avian Influenza A Virus	B-Lymphocytes	Birds
CD8B1 gene	Cessation of life	China	Country	

Thank you for your feedback!


[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

## Influenza Viral Pathogenesis

Project Number 1ZIAAI000986-13		Contact PI/Project Leader TAUBENBERGER, JEFFERY		Awardee Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	
Morbidity - disease rate		Mus	Neuraminidase	Pathogenesis	Pathogenicity
Read More					

### Details

Contact PI/ Project Leader	Other PIs	Program Official
Name <a href="#">TAUBENBERGER, JEFFERY</a> 	Not Applicable	Name
Title		Contact
Contact Email not available		Email not available

### Organization

Name NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	Department Type Unavailable	State Code
City	Organization Type Unavailable	Congressional District
Country		

### Other Information

FOA	Administering Institutes or Centers	Project Start Date
Study Section	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	Project End Date
Fiscal Year 2019	Award Notice Date	Budget Start Date
	DUNS Number CFDA Code	Budget End Date











### Project Funding Information for 2019

Total Funding \$1,495,401	Direct Costs \$0	Indirect Costs \$0
Year	Funding IC	
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$1,495,401

NIH Categorical Spending	<a href="#">Click here for more information on NIH Categorical Spending</a>	
Funding IC	FY Total Cost by IC	NIH Spending Category

Thank you for your feedback!

[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

## Influenza Viral Pathogenesis

Project Number 1ZIAAI000986-13	Contact PI/Project Leader TAUBENBERGER, JEFFERY	Awardee Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
-----------------------------------	---	---

Infectious  
Diseases;  
Influenza;  
Pneumonia &  
Influenza;  
Prevention;  
Vaccine  
Related;

### Sub Projects

No Sub Projects information available for 1ZIAAI000986-13

### Publications

No Publications available for 1ZIAAI000986-13

### Patents

No Patents information available for 1ZIAAI000986-13

### Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1ZIAAI000986-13

### Clinical Studies

No Clinical Studies information available for 1ZIAAI000986-13











### News and More

#### Related News Releases

No news release information available for 1ZIAAI000986-13

Thank you for your feedback!

[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

## Influenza Viral Pathogenesis

Project Number	Contact PI/Project Leader	Awardee Organization
1ZIAAI000986-13	TAUBENBERGER, JEFFERY	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

### Similar Projects

No Similar Projects information available for 1ZIAAI000986-13

Thank you for your feedback!